Who was studied?
Adults with type 2 diabetes were randomized to retatrutide, placebo or dulaglutide. HbA1c change at 24 weeks was the primary endpoint.
- Participants
- 281 adults
- Duration
- 36 weeks
- Funding
- Eli Lilly
What did the study find?
At 36 weeks, mean weight reduction in the 12 mg escalation group was 16.94%, versus 3.00% with placebo and 2.02% with dulaglutide 1.5 mg. The paper also reports glucose-lowering efficacy.
What should you keep in mind?
This was a phase 2 comparison with a particular dulaglutide regimen, not all diabetes treatments. Gastrointestinal adverse events and different escalation groups affect interpretation.
Why it matters
The study extends the question beyond weight loss to glycemic control. It does not establish an approved prescription or a personal dosing schedule.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a phase 2 trial
Published 2023 · PMID 37385280 · DOI 10.1016/S0140-6736(23)01053-X
Summary by Peptide Lit, checked against the original abstract on October 7, 2026. Read the complete paper for detailed methods and safety results. This page explains published research; it does not recommend a treatment or dose.